Applying targeted NGS of 57 thyroid-cancer-related genes demonstrates the expected mutations in BRAF and RET. In our cohort, BRAF mutation is the most prevalent alternation, aligned with many landmark researches (9, 23, 24). The gene discussed is RET; the disease is thyroid cancer.